![Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3](https://oncodaily.com/pub/uploads/2023/09/E22EB883-1E94-40EA-8836-08F8414AE8BA-e1700466783778-1280x1024.jpeg)
Photo from Andres Gomez/Twitter
Nov 20, 2023, 03:53
Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3
Andres Gomez, Associate Professor at the Autonomous University of Nuevo León, Monterrey, Mexico, posted on X/Twitter:
“This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3 and why Yadith Lopez will present a poster comparing pre-post outcomes in the American Society of Hematology 23.
AML in India commentary The Lancet Haematology mirrors Mexico.”
For the article click here.
Source: Andres Gomez/Twitter
Jul 26, 2024, 08:02